{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["izalontamab brengitecan (BL-B01D1)"]],"indication":"locally advanced or metastatic solid tumors","name":"NCT05785039","nct_id":"NCT05785039","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05785039. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.","label":"Study treatment","type":"EXPERIMENTAL"}],"collaborators":["Baili-Bio (Chengdu) Pharmaceutical Co., Ltd."],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Urinary System Tumor","Solid Tumor"],"enrollment":{"count":76,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BL-B01D1","otherNames":["iza-bren","izalontamab brengitecan","BMS-986507"],"type":"DRUG"}],"last_update":"2026-08-27","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","official_title":"Phase IIa/IIb Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-B01D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase IIa: Recommended Phase II Dose (RP2D)","timeFrame":"Up to approximately 24 months"},{"measure":"Phase IIb: Objective response rate (ORR)","timeFrame":"Up to approximately 24 months"}],"references":[],"start_date":{"date":"2023-04-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","url":"https://clinicaltrials.gov/study/NCT05785039"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05785039"}